In which oncologic indications are nitrosourea agents (carmustine, lomustine, fotemustine) used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Nitrosourea Agents: Primary Oncologic Indications

Nitrosourea agents (carmustine, lomustine, fotemustine) are primarily used in brain tumors—specifically gliomas including glioblastoma, astrocytoma, oligodendroglioma, and other high-grade gliomas—as well as in relapsed/refractory lymphomas (both Hodgkin's and Non-Hodgkin's), multiple myeloma, and metastatic melanoma. 1

Brain Tumors (Primary Indication)

Nitrosoureas represent one of the most active drug classes for malignant gliomas 2. According to FDA labeling and EANO guidelines:

FDA-Approved Brain Tumor Indications (Carmustine):

  • Glioblastoma (IDH wild-type and IDH-mutant, WHO grade 4)
  • Astrocytoma (various grades including anaplastic)
  • Brainstem glioma
  • Medulloblastoma
  • Ependymoma
  • Metastatic brain tumors 1

Clinical Use Pattern in Gliomas:

The 2021 EANO guidelines position nitrosoureas as second-line therapy at progression/recurrence for multiple glioma subtypes 3:

  • Glioblastoma (IDH wild-type, WHO grade 4): Nitrosoureas are recommended at progression after temozolomide chemoradiotherapy
  • IDH-mutant astrocytomas (WHO grades 3-4): Nitrosoureas serve as treatment options at recurrence
  • Diffuse midline gliomas (H3 K27M-mutant): Nitrosoureas recommended at progression
  • Diffuse hemispheric gliomas (H3.3 G34-mutant): Nitrosoureas at recurrence

Specific agents used: Lomustine is most commonly employed (often in PCV regimen with procarbazine and vincristine), carmustine (including wafer formulation for local delivery), and fotemustine 3, 2.

Important caveat: Re-exposure to nitrosoureas shows limited activity in tumors without MGMT promoter methylation 3.

Hematologic Malignancies

Multiple Myeloma:

Carmustine is FDA-approved in combination with prednisone for multiple myeloma 1.

Lymphomas:

  • Relapsed or refractory Hodgkin's lymphoma: Carmustine approved in combination with other drugs 1
  • Relapsed or refractory Non-Hodgkin's lymphomas: Carmustine approved in combination regimens 1
  • Fotemustine has shown efficacy in high-dose chemotherapy regimens (FEAM protocol) for relapsed/refractory Hodgkin lymphoma, with 2-year PFS of 73.8% 4

Melanoma

Fotemustine specifically demonstrates activity in:

  • Disseminated malignant melanoma: 24.2% overall response rate in multicenter trials 5
  • Cerebral metastases from melanoma: 25% response rate 5
  • Hepatic metastases from ocular melanoma: ~40% response rate via intraarterial hepatic administration 5

The 2015 ESMO melanoma guidelines mention fotemustine as a cytotoxic option when immunotherapy and targeted therapy are unavailable 6.

Key Toxicity Considerations

Myelosuppression is the dose-limiting toxicity:

  • Carmustine/lomustine cause delayed (4-6 weeks) and often cumulative leukopenia and thrombocytopenia, unlike temozolomide's early (2-3 weeks) effects 3
  • Pulmonary fibrosis is dose-related, particularly with carmustine; patients receiving >1400 mg/m² cumulative dose face significantly higher risk 1
  • Lomustine has lower pulmonary toxicity than carmustine 3

Formulation-Specific Uses

Carmustine wafers (Gliadel): FDA-approved for local delivery via implantation into post-surgical cavity for:

  • Newly diagnosed high-grade gliomas (WHO grade 3 or 4)
  • Recurrent glioblastoma 3, 7

The benefit was modest and not statistically significant after excluding WHO grade 3 tumors (mostly IDH-mutant) from analysis 3.

References

2
Research

Nitrosoureas in the Management of Malignant Gliomas.

Current neurology and neuroscience reports, 2016

Related Questions

At what cumulative dose of nitrosourea agents (e.g., carmustine, lomustine, fotemustine) does the risk of pancytopenia become significant?
What are the 2026 American Thoracic Society (ATS) guidelines for the use of non‑invasive ventilation (NIV) in adults with acute hypercapnic respiratory failure, acute cardiogenic pulmonary edema, or high risk of post‑extubation respiratory failure?
In an adult on mirtazapine 30 mg daily with persistent generalized anxiety disorder symptoms, should I add buspirone or switch to escitalopram (Lexapro)?
How should diarrhea be managed in a healthy 13-month-old infant?
What dose of Ed‑A‑Hist DM (chlorpheniramine 4 mg, dextromethorphan 15 mg, phenylephrine 10 mg per 5 mL) should be given to a child weighing 16.33 kg?
What is the appropriate dosing regimen for theophylline, including loading and maintenance doses, target serum concentrations, and contraindications?
What is the most appropriate method to detect a ureteral leak?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.